د.عبدالله علي الشرم

استشاري اورام

[Dr. Nina Niu Sanford @NiuSanford]

RTOG 0848: neg overall, but benefit in pN0 (adj chemoRT improved OS 5yr 48% v 29%).

Caveats: small N0 subgroup (N=91), gem chemo, pre neoadj era.

My main takeaway: RT has role in (select) resectable PDAC & future trials need to focus on biologically favorable subset. @OncoAlert

[Ferran Fece de la Cruz @FerranFeceCruz]

What do we want? Phase 3!
When do we want it? Now!

#RASRevolution #Daraxonrasib #PRMT5 #pancsm

[Paolo Tarantino @PTarantinoMD]

What do you mean 92% ORR in pretreated pancreatic cancer?! 🤯

[Richard Y. Ebright, MD, PhD @RYEbright]

Last year, we reported that KRAS+PRMT5 is synergistic in MTAP-null PDAC (https://t.co/mIc6hkbMpL). Today, the first clinical data for a KRAS/PRMT5 combination was reported, with an incredible 92% ORR.

RAS inhibitors are the present, but combinations are the future!!
$TNGX $RVMD

[Dr Amol Akhade @SuyogCancer]

How to treat metastatic papillary RCC ?
Nice slides from talks by @charlesbnguyen and @ADESAIONCMD @asco #asco26

[Erman Akkus @Erman_Akkus]

🏥T4, MRF, CRM in rectal cancer for medical oncologists

✅All related but different concepts
➡️T4b but MRF- (e.g. upper third tm)
➡️MRF by MRI, CRM by pathological
➡️MRF- but CRM+ (e.g. technically hard surgery)

PS: prepared by AI. Surgeon, pathologist, radiologist colleagues may correct if wrong

#cancer #oncology #MedX #rectal #GI @OncoAlert

[Erman Akkus @Erman_Akkus]

Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial | Clinical Cancer Research | American Association for Cancer Research https://t.co/dIoydIYvru

[Dr. Andrew Loblaw @DrAndrewLoblaw]

In comparison, what’s the relapse rate after radical Nephrectomy?

What say you Open Evidence…?

Maybe time for an RCT @_ShankarSiva ?

[Erman Akkus @Erman_Akkus]

Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial | Nature Medicine https://t.co/H0FkPENBvn

[Erman Akkus @Erman_Akkus]

Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial @OncoAlert https://t.co/fiFLKKhBYV

[Erman Akkus @Erman_Akkus]

⚛️Lu-DOTA vs. sunitinib in metastatic progressive pancreatic NET
OCLURANDOM

✅12mo PFS
80.5% vs 41.9%

👉https://t.co/dmAPeq92wC

#cancer #oncology #MedX @OncoAlert @OncoThor @UGrewalMD

[Erman Akkus @Erman_Akkus]

A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3 - Annals of Oncology https://t.co/ilN29WV1s4

[Katy Beckermann @katy_beckermann]

Same target, three carrier-isotope platforms, three toxicity profiles.
🔬 ²²⁵Ac-PSMA-617 (small molecule · alpha): Salivary uptake yes.
🔬 ²²⁵Ac-rosopatamab (antibody · alpha): Minimal salivary/renal uptake. Thrombocytopenia replaces xerostomia
🔬 ¹⁷⁷Lu-rosopatamab (antibody · beta): Minimal salivary/renal uptake. Thrombocytopenia replaces xerostomia

The antibody carrier trades salivary toxicity for bone marrow toxicity.

💡 RLT selection is becoming a carrier-and-isotope decision. Organ function, prior therapy, and toxicity tolerance will be a factor

#ProstateCancer #mCRPC #PSMA #Theranostics #RLT #GUOnc #ASCO26

[Mirrors of Medicine @mirrorsmed]

Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study

https://t.co/xbv92OSepc

With nearly 43 months of follow-up, enfortumab vedotin + pembrolizumab (EV+P) continues to outperform chemotherapy in previously untreated locally advanced/metastatic urothelial carcinoma.

📊 Efficacy
• Median OS: 33.6 vs 15.9 months
• 42-month OS: 44.0% vs 24.6%
• HR 0.53 (95% CI 0.45–0.63)
• No new safety signals with longer exposure

💡 Depth of response
Among responders, 45.1% achieved CR with EV+P, and ~2/3 of CRs evolved from an initial PR, typically after ~5 additional cycles.
Among CR patients, >80% were alive at 3.5 years, with median OS not reached.
🔄 Post-progression therapy
Platinum-based chemo remained the most common next line after EV+P (30.5%), with modest response rates (~20%).

🔬 Take-home: EV+P delivers durable survival benefit and deepening responses over time, reinforcing its role as standard first-line therapy in la/mUC. #BladderCancer

@tompowles1
@MichvdHeijden
@MattGalsky
@y_loriot
@IyerGopa
@JCensits
@mar_nataliya
@CVulsteke
@KalaSridh
@shilpaonc
@OncoAlert

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer : TALAPRO3

https://t.co/1nldIdOdZo

In metastatic androgen pathway modulation–sensitive (APMS) #ProstateCancer with HRR gene alterations, talazoparib + enzalutamide was compared with enzalutamide alone in a phase 3, double-blind trial (~600 patients).

📊 Efficacy
At 3 years, imaging-based PFS was 77% vs 56%, translating to a 52% reduction in risk of progression or death (HR 0.48; P<0.001).
Interim OS showed a numerical trend:
• 78% vs 72% (HR 0.77; 95% CI 0.56–1.04)

⚠️ Safety
• Serious AEs: 42% vs 32%
• Grade ≥3 anemia: 51%
• Two treatment-related deaths in the talazoparib arm

💡 Take-home: Adding talazoparib significantly improves PFS in HRR-altered APMS prostate cancer, supporting earlier use of PARP inhibition, but with increased hematologic toxicity.

@neerajaiims
@AzadOncology
@quimmateo
@nealshore
@cvulsteke

@OncoAlert
@Silke_Gillessen
@AOmlin
@weoncologists

[Angela Lamarca @DrAngelaLamarca]

Last, but not least, @FIGHT302 presented at @ASCO #ASCO26

Pemigatinib vs CisGem for #FGFR2 fusion +ve #CCA in the #FirstLine setting

😓Early interruption (slow accrual) - limited power
🙂Trend - better PFS
😊Significantly increased ORR

👉Supports use of iFGFR in CCA

[Oncology Brothers @OncBrothers]

Why is RASolute-302 being celebrated? Because historically, we have had limited options for pancreatic cancer. We definitely need to do better but RAS is now finally actionable!!! Previous data in this space….

#pancsm #gism #OncTwitter #MedTwitter #daraxonrasib

[Arndt Vogel @ArndtVogel]

Phase III CR-SEQUENCE trial of FOLFOX+pani followed by FOLFIRI+beva (SEQ1) versus FOLFOX + beva followed by FOLFIRI + pani (SEQ2) in RAS WT, left-sided mCRC
#ASCO26
👉no difference in 36mo PFS rate
👉higher ORR with pain
🧐ctDNA and molecular analysis awaited
@myesmo @ASCO

[Dr. Nina Niu Sanford @NiuSanford]

MIRACLE-2: RT to primary/mets -&gt; chemo + tislelizumab in MSS unresectable met rectal ca (N=50): 68% ORR &amp; median OS 23 mo.

Early, single-arm data, but ~1 in 5 pts reached NED.

Suggests RT + systemic + PD1 blockade could overcome immune resistance in MSS mCRC. #ASCO26 @OncoAlert

[Samuel Hume @DrSamuelBHume]

4. What's next for Daraxonrasib? More trials!

1st line in metastatic pancreatic cancer, and after surgery in resectable disease; in lung cancer; and in other solid cancers, like colorectal